LeMaitre Vascular, Inc. ( LMAT ) NASDAQ Global Market

Cena: 84.01 ( 0.19% )

Aktualizacja 07-03 17:05
NASDAQ Global Market
Branża: Medical - Instruments & Supplies
Statystyki
Dywidendy
Rekomendacje
Wyceny
Wskaźniki
Analiza techniczna

Notowania:

Informacje o spółce:
Sektor: Zdrowie
Branża: Medical - Instruments & Supplies
Zatrudnienie: 614
Giełda: NASDAQ Global Market
Ilość akcji w obrocie: 89%
Ilość akcji: 22 263 200
Debiut giełdowy: 2006-10-19
WWW: https://www.lemaitre.com
CEO: Mr. George W. LeMaitre
Adres: 63 Second Avenue
Siedziba: 01803 Burlington
ISIN: US5255582018
Opis firmy:

Projekty Lemaitre Vascular, Inc., rynki, sprzedaży, usług i wspiera urządzenia medyczne i implanty w leczeniu chorób naczyniowych na naczyni na całym świecie. Oferuje angioskop, cewnik światłowodowy używany do oglądania światła naczynia krwionośnego; cewniki embrionalne w celu usunięcia skrzepów krwi z tętnic lub żył; cewniki okluzji, które tymczasowo zamykają przepływ krwi; cewniki perfuzyjne do perfuzji krwi i innych płynów do naczyń naczyniowych; oraz cewniki trombektomii, które mają silikonowy balon do usuwania zakrzepów w układzie żylnym. Firma zapewnia również złoża szyjnych, które tymczasowo przetaczają krew do mózgu podczas usuwania płytki z tętnicy szyjnej podczas operacji endarterektomii szyjnej; oraz taśma radiopacyjna, taśma medyczna nałożona na skórę, która umożliwia interwencjonistom przeniesienie między wnętrzem a zewnętrzną częścią ciała pacjenta i pozwala im zlokalizować dopływy lub zmiany pod skórą. Ponadto oferuje Valvulotomy, które przecinają lub zakłócają zawory w żyłach odpiszeczkowych, aby funkcjonować jako tętnica do przenoszenia krwi z powodu chorych tętnic do dolnej części nogi lub stopy; i przeszczepy naczyniowe do ominięcia lub wymiany chorych tętnic. Ponadto firma zapewnia łatki naczyniowe i serca, które są wykorzystywane do zamknięcia naczyń po interwencji chirurgicznej; oraz systemy zamykania do przyczepności naczyń do siebie za pomocą klipsów tytanowych zamiast szwów. Wymaga swoich produktów za pośrednictwem Bezpośredniej Siłę sprzedaży i dystrybutorów. Firma była wcześniej znana jako Vascutech, Inc. i zmieniła nazwę na LEMAITRE VASCULL, Inc. w kwietniu 2001 r. Lemaitre Vascular, Inc. został zarejestrowany w 1983 roku i ma siedzibę w Burlington w stanie Massachusetts.

Wskaźniki finansowe
Kapitalizacja (USD) 1 898 069 685
Aktywa: 377 025 000
Cena: 84.01
Wskaźnik Altman Z-Score: 31.8
Stabilny (niskie ryzyko bankructwa)
Dywidenda: 1
P/E: 42.6
Ilość akcji w obrocie: 89%
Średni wolumen: 188 729
Ilość akcji 22 594 400
Wskaźniki finansowe
Przychody TTM 213 029 000
Zobowiązania: 45 951 000
Przedział 52 tyg.: 71.42 - 109.58
Piotroski F-Score: 7
Silny (dobra jakość finansowa)
EPS: 2.0
P/E branży: 29.9
Beta: 0.885
Raport okresowy: 2025-07-30
WWW: https://www.lemaitre.com
Zarząd
Imie i Nazwisko Stanowisko Wynagrodzenie Rok urodzenia
Mr. David B. Roberts President & Director 634 852 1964
Mr. Joseph P. Pellegrino Jr. Chief Financial Officer, Secretary & Director 566 190 1965
Mr. Trent G. Kamke Senior Vice President of Operations 445 380 1971
Dr. George D. LeMaitre Founder and Chairman of Scientific Advisory Board 118 482 1934
Mr. George W. LeMaitre Chairman & Chief Executive Officer 1 120 797 1965
Mr. Jonathan W. Ngau Senior Vice President of Information Technology 0 1974
Mr. Daniel J. Mumford Senior Director of Human Resources 0 1982
Ms. Kimberly L. Cieslak Vice President of Marketing 0 1973
Mr. Maik D. Helmers Senior Vice President of Sales – Central Europe 0 1974
Mr. Ryan H. Connelly Senior Vice President of Advanced Manufacturing Engineering 0 1977
Wiadomości dla LeMaitre Vascular, Inc.
Tytuł Treść Źródło Aktualizacja Link
LeMaitre to Present at the Bank of America Securities 2025 Healthcare Conference BURLINGTON, Mass., May 05, 2025 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that David Roberts, President, will present at the Bank of America Securities 2025 Healthcare Conference on Tuesday, May 13, 2024, at 5:00 PM PDT at the Encore at the Wynn Hotel in Las Vegas, NV. globenewswire.com 2025-05-05 20:39:00 Czytaj oryginał (ang.)
LeMaitre Vascular, Inc. (LMAT) Q1 2025 Earnings Call Transcript LeMaitre Vascular, Inc. (LMAT) Q1 2025 Earnings Call Transcript seekingalpha.com 2025-05-02 03:17:09 Czytaj oryginał (ang.)
LeMaitre Vascular (LMAT) Lags Q1 Earnings Estimates LeMaitre Vascular (LMAT) came out with quarterly earnings of $0.48 per share, missing the Zacks Consensus Estimate of $0.50 per share. This compares to earnings of $0.44 per share a year ago. zacks.com 2025-05-01 22:20:34 Czytaj oryginał (ang.)
LeMaitre Q1 2025 Financial Results BURLINGTON, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq: LMAT), a provider of vascular devices, implants, and services, today reported Q1 2025 results, announced a quarterly dividend of $0.20/share, and provided guidance. globenewswire.com 2025-05-01 20:05:00 Czytaj oryginał (ang.)
The Elephant In The Room - March Dividend Income Report I've sold some higher-yielding stocks and reduced my portfolio yield in March. The goal was to get closer to my core strategy of investing only in companies with low dividend yields, but high dividend growth potential. While my portfolio yield decreased from 4% to 3.5%, my 5-year CAGR dividend growth rate went from 8% to 11%. Despite much uncertainty, the Canadian stock market has remained relatively strong since the beginning of the year. seekingalpha.com 2025-04-21 10:30:00 Czytaj oryginał (ang.)
LeMaitre (LMAT) Soars 7.7%: Is Further Upside Left in the Stock? LeMaitre (LMAT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road. zacks.com 2025-04-10 16:40:48 Czytaj oryginał (ang.)
LeMaitre Will Announce First Quarter 2025 Earnings Results May 1, 2025 BURLINGTON, Mass., April 07, 2025 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it will release its first quarter 2025 financial results on Thursday, May 1, 2025, after the market close. The company has scheduled a conference call for 5:00 PM EDT the same day to discuss the results, business highlights, and company outlook. globenewswire.com 2025-04-07 19:56:00 Czytaj oryginał (ang.)
4 Low-Beta Healthcare Stocks to Beat Trump's Tariff Blues Healthcare stocks like GLID, COR, FMS and LMAT are a safe bet during times of market volatility. zacks.com 2025-04-04 13:30:24 Czytaj oryginał (ang.)
Small-Cap Dividend Stocks: Hidden Gems Or High-Risk Plays? - Top U.S. And Canadian Ones Over the past decade, the iShares S&P/TSX SmallCap Index ETF has underperformed broader markets due to its heavy exposure to resource-heavy sectors like energy and materials. Acme's dividend track record spans over 15 years, with a modest but steady payout. Debt levels remain low, and management is highly focused on operational efficiency. With regulated pricing, recurring revenue, and defensive characteristics, York Water is a favorite for income-seekers looking for small-cap stability. seekingalpha.com 2025-04-04 11:47:00 Czytaj oryginał (ang.)
LeMaitre to Present at the 24th Annual Needham Virtual Healthcare Conference BURLINGTON, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that management will present at the 24th Annual Needham Virtual Healthcare Conference on Tuesday, April 8, 2025, at 3:45 PM EDT. globenewswire.com 2025-04-01 19:20:00 Czytaj oryginał (ang.)
Stocks Falling On Earnings - What To Do? February Dividend Income Report Alimentation Couche-Tard has several growth vectors in place with a clear 5-year plan, including organic growth and growth by acquisition. Starting in March, I will increase my Smith Manoeuvre contribution from $500 to $750 monthly. CCL Industries reported another good quarter with revenue up 9% and EPS up 5%. seekingalpha.com 2025-03-29 12:30:00 Czytaj oryginał (ang.)
3 Reasons Growth Investors Will Love LeMaitre (LMAT) LeMaitre (LMAT) could produce exceptional returns because of its solid growth attributes. zacks.com 2025-03-25 15:46:04 Czytaj oryginał (ang.)
Precision Optics Appoints Joseph P. Pellegrino, Jr. to Board of Directors GARDNER, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ: POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, is pleased to announce the appointment of Joseph P. globenewswire.com 2025-03-20 11:00:00 Czytaj oryginał (ang.)
3 Best Earnings Growth Stocks to Buy in March: CAKE, LMAT, HURN The Cheesecake Factory, LeMaitre Vascular and Huron Consulting Group are currently displaying superb earnings growth. zacks.com 2025-03-06 10:50:31 Czytaj oryginał (ang.)
When Do You Sell A Winner? - January Dividend Income Report BlackRock is an interesting case study as I sold it for a nice profit even though the company's investment thesis is still intact. However, some metrics aren't as strong as before. I have a Telus position in one of my other portfolios. I've actively monitored its cash flow metrics. Brookfield Renewable reported another solid quarter with FFO per unit up 21%. The company's hydroelectric, wind, solar, and distributed energy businesses all contributed positively despite weaker North American hydrology affecting hydroelectric generation. seekingalpha.com 2025-03-04 13:17:00 Czytaj oryginał (ang.)
Best Momentum Stocks to Buy for March 4th OPCH and LMAT made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on March 4, 2025. zacks.com 2025-03-04 13:00:53 Czytaj oryginał (ang.)
New Strong Buy Stocks for March 4th OPCH, LMAT, C, FFIN and IBCP have been added to the Zacks Rank #1 (Strong Buy) List on March 4, 2025. zacks.com 2025-03-04 09:15:41 Czytaj oryginał (ang.)
LeMaitre to Participate at Upcoming Investor Conferences in March BURLINGTON, Mass., March 03, 2025 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that management will be participating in three upcoming investor conferences in March. globenewswire.com 2025-03-03 19:06:00 Czytaj oryginał (ang.)
LeMaitre (LMAT) Upgraded to Buy: Here's What You Should Know LeMaitre (LMAT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. zacks.com 2025-03-03 15:05:31 Czytaj oryginał (ang.)
LeMaitre Vascular, Inc. (LMAT) Q4 2024 Earnings Call Transcript LeMaitre Vascular, Inc. (NASDAQ:LMAT ) Q4 2024 Earnings Conference Call February 27, 2025 5:00 PM ET Company Participants J.J. Pellegrino - Chief Financial Officer George LeMaitre - Chief Executive Officer Dave Roberts - President Conference Call Participants Nathan Treybeck - Wells Fargo Danny Stauder - Citizens JMP Matthew Park - Cantor Fitzgerald Frank Takkinen - Lake Street Capital Markets Michael Petusky - Barrington Research Jim Sidoti - Sidoti & Company Operator Welcome to the LeMaitre Vascular Q4 2024 Financial Results Conference Call. seekingalpha.com 2025-02-28 01:16:54 Czytaj oryginał (ang.)
LeMaitre Vascular (LMAT) Meets Q4 Earnings Estimates LeMaitre Vascular (LMAT) came out with quarterly earnings of $0.49 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.38 per share a year ago. zacks.com 2025-02-27 21:45:24 Czytaj oryginał (ang.)
LeMaitre Q4 2024 Financial Results BURLINGTON, Mass., Feb. 27, 2025 (GLOBE NEWSWIRE) -- LeMaitre (Nasdaq:LMAT), a provider of vascular devices, implants, and services, reported Q4 2024 results, announced an increased quarterly dividend of $0.20/share (+25%), and provided guidance. globenewswire.com 2025-02-27 18:05:00 Czytaj oryginał (ang.)
LeMaitre Will Announce Fourth Quarter 2024 Earnings Results February 27, 2025 BURLINGTON, Mass., Jan. 27, 2025 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it will release its fourth quarter 2024 financial results on Thursday, February 27, 2025, after the market close. The company has scheduled a conference call for 5:00 PM EST the same day to discuss the results, business highlights, and company outlook. globenewswire.com 2025-01-27 17:15:00 Czytaj oryginał (ang.)
The Most Underrated Mistake Destroying Your Retirement - December Dividend Income Report Since its inception, my portfolio has been up 177%, with a 15% annualized growth rate. At this time, I'm thinking of adding a little bit more of Telus to this portfolio. The stock has been significantly penalized, while Telus' situation isn't that catastrophic (free cash flow and cash from operations improved throughout 2024). After selling Texas Instruments, the only stock I could see myself selling in 2025 would be BlackRock. seekingalpha.com 2025-01-27 09:12:00 Czytaj oryginał (ang.)
4 Healthcare Stocks Rising More Than 50% in 2024 With Room to Grow Medical stocks are expected to reap the benefits of affordable health insurance plans, rising surgeries and widespread adoption of telehealth services in the days ahead. However, inflation and supply-chain woes may act as spoilsport. zacks.com 2024-12-24 12:11:11 Czytaj oryginał (ang.)
LeMaitre Vascular Announces Proposed Convertible Senior Notes Offering BOSTON, Dec. 16, 2024 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (“LeMaitre”) (Nasdaq: LMAT) today announced its intention to offer, subject to market and other conditions, $150,000,000 aggregate principal amount of Convertible Senior Notes due 2030 (the “notes”) in a private offering (the “offering”) to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). LeMaitre also expects to grant the initial purchasers of the notes an option to purchase, for settlement within a period of 13 days from, and including, the date the notes are first issued, up to an additional $22,500,000 aggregate principal amount of notes. globenewswire.com 2024-12-16 09:57:00 Czytaj oryginał (ang.)
Final Trade: LMAT, GOOGL, IBM, GILD The final trades of the day with CNBC's Melissa Lee and the Fast Money traders. youtube.com 2024-12-10 20:50:26 Czytaj oryginał (ang.)
RMD vs. LMAT: Which Stock Is the Better Value Option? Investors looking for stocks in the Medical - Products sector might want to consider either ResMed (RMD) or LeMaitre Vascular (LMAT). But which of these two companies is the best option for those looking for undervalued stocks? zacks.com 2024-11-26 14:40:45 Czytaj oryginał (ang.)
LeMaitre to Participate at Upcoming Investor Conferences in December BURLINGTON, Mass., Nov. 25, 2024 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it is participating in two upcoming investor conferences in December. globenewswire.com 2024-11-25 19:20:00 Czytaj oryginał (ang.)
LeMaitre Vascular: The Market Is Catching On To This Dividend Growth Story LeMaitre continues to expand in the peripheral vascular disease market, with recent revenue gains driven by premium pricing and international growth. Its strong dividend growth of 14.3% this year and double-digit CAGR over the past five years are particularly appealing. With a high-margin, low-competition niche and accelerating geographic expansion, LeMaitre remains well-positioned for sustained growth. seekingalpha.com 2024-11-03 18:25:33 Czytaj oryginał (ang.)
LeMaitre to Participate at Upcoming Investor Conferences in November BURLINGTON, Mass., Nov. 01, 2024 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that management will be participating in three upcoming investor conferences in November. globenewswire.com 2024-11-01 18:47:00 Czytaj oryginał (ang.)
LeMaitre Vascular, Inc. (LMAT) Q3 2024 Earnings Call Transcript LeMaitre Vascular, Inc. (NASDAQ:LMAT ) Q3 2024 Earnings Conference Call October 33, 2024 5:00 PM ET Company Participants J.J. Pellegrino - Chief Financial Officer George LeMaitre - Chief Executive Officer Dave Roberts - President Conference Call Participants Suraj Kalia - Oppenheimer Rick Wise - Stifel Brett Fishbin - KeyBanc Jason Wittes - Roth Danny Stauder - Citizens JMP Michael Petusky - Barrington Research Frank Takkinen - Lake Street Capital Markets Jim Sidoti - Sidoti & Company Ross Osborn - Cantor Fritzgerald Operator Welcome to the LeMaitre Vascular Q3 2024 Financial Results Conference Call. seekingalpha.com 2024-10-31 21:59:01 Czytaj oryginał (ang.)
LeMaitre Vascular (LMAT) Surpasses Q3 Earnings and Revenue Estimates LeMaitre Vascular (LMAT) came out with quarterly earnings of $0.49 per share, beating the Zacks Consensus Estimate of $0.44 per share. This compares to earnings of $0.33 per share a year ago. zacks.com 2024-10-31 20:20:30 Czytaj oryginał (ang.)
LeMaitre Q3 2024 Financial Results BURLINGTON, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- LeMaitre (Nasdaq:LMAT), a provider of vascular devices, implants, and services, reported Q3 2024 results, announced a $0.16/share quarterly dividend, and provided guidance. globenewswire.com 2024-10-31 18:05:00 Czytaj oryginał (ang.)
BAX or LMAT: Which Is the Better Value Stock Right Now? Investors looking for stocks in the Medical - Products sector might want to consider either Baxter International (BAX) or LeMaitre Vascular (LMAT). But which of these two companies is the best option for those looking for undervalued stocks? zacks.com 2024-10-18 16:45:30 Czytaj oryginał (ang.)
LeMaitre Will Announce Third Quarter 2024 Earnings Results October 31, 2024 BURLINGTON, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it will release its third quarter 2024 financial results on Thursday, October 31, 2024, after the market close. The company has scheduled a conference call for 5:00 PM ET the same day to discuss the results, business highlights, and company outlook. globenewswire.com 2024-10-15 20:34:00 Czytaj oryginał (ang.)
BAX vs. LMAT: Which Stock Is the Better Value Option? Investors looking for stocks in the Medical - Products sector might want to consider either Baxter International (BAX) or LeMaitre Vascular (LMAT). But which of these two stocks presents investors with the better value opportunity right now? zacks.com 2024-10-02 16:46:43 Czytaj oryginał (ang.)
All You Need to Know About LeMaitre (LMAT) Rating Upgrade to Strong Buy LeMaitre (LMAT) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. zacks.com 2024-09-23 17:02:23 Czytaj oryginał (ang.)
LeMaitre to Participate at Upcoming Investor Conferences in September BURLINGTON, Mass., Aug. 27, 2024 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that management will be participating in three upcoming investor conferences in September. globenewswire.com 2024-08-27 20:54:00 Czytaj oryginał (ang.)
LeMaitre (LMAT) Upgraded to Strong Buy: Here's Why LeMaitre (LMAT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy). zacks.com 2024-08-06 17:01:36 Czytaj oryginał (ang.)
Best Momentum Stock to Buy for August 6th HWKN, PPC and LMAT made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on August 6, 2024. zacks.com 2024-08-06 14:06:08 Czytaj oryginał (ang.)
LeMaitre Vascular, Inc. (LMAT) Q2 2024 Earnings Call Transcript LeMaitre Vascular, Inc. (NASDAQ:LMAT ) Q2 2024 Results Conference Call August 1, 2024 5:00 PM ET Company Participants J.J. Pellegrino - Chief Financial Officer George LeMaitre - Chief Executive Officer Dave Roberts - President Conference Call Participants Rick Wise - Stifel Jason Wittes - ROTH Danny Stauder - Citizens JMP Michael Sarcone - Jefferies Michael Petusky - Barrington Research Frank Takkinen - Lake Street Capital Markets Operator Welcome to the LeMaitre Vascular Q2 2024 Financial Results Conference Call. seekingalpha.com 2024-08-02 01:17:05 Czytaj oryginał (ang.)
LeMaitre Vascular (LMAT) Surpasses Q2 Earnings and Revenue Estimates LeMaitre Vascular (LMAT) came out with quarterly earnings of $0.52 per share, beating the Zacks Consensus Estimate of $0.47 per share. This compares to earnings of $0.37 per share a year ago. zacks.com 2024-08-01 22:55:33 Czytaj oryginał (ang.)
LeMaitre Q2 2024 Financial Results BURLINGTON, Mass., Aug. 01, 2024 (GLOBE NEWSWIRE) -- LeMaitre (Nasdaq:LMAT), a provider of vascular devices, implants and services, today reported Q2 2024 results, announced a $0.16/share quarterly dividend and provided guidance. globenewswire.com 2024-08-01 20:05:00 Czytaj oryginał (ang.)